CI Global Health Sciences Corporate Class

Series F USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
CAD Total net assets ($CAD)
As at 2026-03-31
$135.1 million
NAVPS
As at 2026-05-06
$25.6813
MER (%)
As at 2025-09-30
1.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.5033

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 324
A ISC 301
DSC SO* 401
LL SO 1401
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-04-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-9.94% -1.28% -9.86% -3.62% -0.89% -1.25% -2.73% 2.29% 6.61%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.5033
2021-03-26 0.1714
2020-12-18 0.2724
2020-09-25 0.2584
2020-06-26 0.1886
Payable date Total
2020-03-20 0.4395
2019-12-13 0.2744
2019-09-27 0.3063
2019-06-21 0.2883
2019-03-22 0.4530

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series F USD
 
Portfolio allocations4 As at 2026-03-31
Asset allocation (%)
  • US Equity 81.98
  • International Equity 14.59
  • Cash and Equivalents 3.44
  • Other -0.01
Sector allocation (%)
  • Healthcare 93.49
  • Cash and Cash Equivalent 3.44
  • Exchange Traded Fund 3.08
  • Other -0.01
Geographic allocation(%)
  • United States 81.95
  • United Kingdom 9.24
  • Canada 3.42
  • Switzerland 3.37
  • Netherlands 2.03
  • Other -0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 13.13%
2. AstraZeneca PLC Drugs 8.20%
3. Thermo Fisher Scientific Inc Healthcare Equipment 8.14%
4. Johnson & Johnson Drugs 7.92%
5. IQVIA Holdings Inc Drugs 6.64%
6. DexCom Inc Healthcare Equipment 5.65%
7. Intuitive Surgical Inc Healthcare Equipment 5.13%
8. Danaher Corp Healthcare Equipment 5.12%
9. Merck & Co Inc Drugs 4.86%
10. Stryker Corp Healthcare Equipment 4.84%
11. Boston Scientific Corp Healthcare Equipment 4.43%
12. CASH Cash and Cash Equivalent 3.41%
13. Vertex Pharmaceuticals Inc Drugs 3.39%
14. AbbVie Inc Drugs 3.15%
15. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.08%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.